Valeant Pharmaceuticals still has plenty of supporters despite the media storm surrounding the company and its businesses practices.
Last night it emerged that Bill Ackman, one of Valeant's most staunch supporters, has upped Pershing Square’s stake in Valeant to 9.9% of the company’s outstanding shares -- a near 70% increase in Pershing's holding before recent declines.
Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for ValueWalk
A worrying trend is starting to show through at large-cap US banks. In recent weeks and months, commercial and industrial loan growth has slowed, prompting analysts to warn of... read more
This is the second part of a multi-part series on Warren Buffett’s early years. Before he acquired Berkshire Hathaway, Warren Buffett managed a number of partnership for select investors, family... read more
ValueWalk's Raul Panganiban interviews George Muzea, the author of "The Vital Few vs The Trivial Many." Intro followed by podcast for all readers and transcript for premiumn subscribers Q4 hedge... read more
Omni Macro Fund netted a return of 0.67% in May, bringing up the year to date gain to +2.7%. In the monthly letter reviewed by ValueWalk, Omni's managers seemed... read more
Speaking at the Invest for Kids conference in Chicago today, hedge fund manager Bill Ackman of Pershing Square Capital Management made a number of bold statements. Ackman's goal to replace... read more
Free Money - This Incredibly Reckless Policy Is Gaining Momentum by Hard Assets Alliance I was sure I misread the title, because everyone instinctively knows this policy is a bad... read more
The hedge fund industry witnessed a fifth consecutive quarterly record of capital inflows during 3Q13 eclipsing $2.51 trillion in fund capital. Hedge Fund Research Inc’s recent report highlights that hedge... read more
Falling Pound Is Nothing But Bad News For UK It is an very interesting time to be a British investor. Since the country voted to leave the European Union at... read more
High yield junk-debt funds are a growing business at the moment, and one of the biggest beneficiaries is The Blackstone Group L.P. (NYSE:BX) according to an article in Businessweek.... read more
Greenlight Capital filed an amended 13F yesterday that disclosed the detail of the fund's investment in Micron Technology, Inc. (NASDAQ:MU). While the hedge fund bought Micron in Q3, it did... read more
Here’s a Tip: Read What Professional Investors Read
ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.
It’s THE resource for value investing and hedge funds. 📈
And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.
Sign up now. 👇
